Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...